Enloplatin
Enloplatin is a water-soluble cancer medication.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Enloplatin is a water-soluble cancer medication. It is a platinum-based antineoplastic investigated for treatment of platinum-refractory ovarian cancer, in which it was demonstrated to have minimal activity.
This cancer is suspected to be at least partially cross-resistant with another third-generation platinum analog, zeniplatin, which also shows minimal antitumor activity in this type of cancer. Enloplatin was found to be cross-resistant with carboplatin.
Like zeniplatin and carboplatin, use of enloplatin causes manageable nephrotoxicity, no significant neurotoxicity or ototoxicity, and dose-limiting myelosuppression. The drug was originally developed by Wyeth, but no further development since 2000 has been reported.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1360792044 under CC BY-SA 4.0; modifications have been made.